traccglobal.com

Pharmaceutical & Manufacturing Consulting

Equipment Selection & Process Setup That Gets You Audit-Ready Faster

Quick Answer: Equipment selection and process setup is the systematic process of choosing the right manufacturing machinery, designing an efficient workflow, and ensuring every step meets GMP, CDSCO/Schedule M (India) or US FDA cGMP standards (USA). Done correctly, it prevents costly re-qualifications, regulatory holds, and batch failures — and sets the foundation for scalable, cost-efficient production from day one.

CDSCO / Schedule M

US FDA cGMP

WHO GMP

ICH Q7 / Q8 / Q9

Pharma · Biotech · Manufacturing

What Is Equipment Selection & Process Setup?

When you’re building or upgrading a pharmaceutical or manufacturing facility, the machines you choose and the way you set up your processes will define your product quality, regulatory status, and profitability for years to come. A poor equipment choice made early can lead to failed qualifications, batches that don’t meet spec, or a full shutdown by regulators.

Equipment selection is the process of identifying the exact machine types, sizes, materials of construction, automation level, and configurations your production needs — aligned with your product type (oral solids, injectables, APIs, biotech, etc.), your batch size, and your regulatory requirements.

Process setup goes further: it means designing the entire manufacturing workflow — from raw material entry to finished product dispatch — so that every step is efficient, documented, validated, and inspection-ready.

Together, these two activities form the backbone of a successful, GMP-compliant manufacturing operation. Whether you’re setting up a new plant in India, upgrading to meet the revised Schedule M deadlines, or building a US FDA-compliant facility for export markets — getting this right the first time saves significant time and money.

WHAT'S INCLUDED IN THIS SERVICE
  • Equipment requirement analysis & URS preparation
  • Vendor evaluation and equipment selection
  • Process flow design and plant layout planning
  • DQ, IQ, OQ, PQ qualification protocols
  • GMP documentation — SOPs, logbooks, batch records
  • CDSCO/Schedule M compliance (India)
  • US FDA / cGMP alignment (USA & export)
  • Process validation and risk assessment (FMEA)
  • Scalability planning for future capacity
  • Training and handover support
2026 Update: CDSCO has mandated mandatory inspections for all pharmaceutical factories from January 2026. MSMEs that missed the Revised Schedule M deadline are now under high-risk scrutiny. If your facility hasn’t completed equipment qualification, now is the time to act.
 

The Real Cost of Getting Equipment Selection Wrong

Companies lose millions every year — not because they bought cheap equipment, but because they bought the wrong equipment. Here’s what’s at stake.

Re-qualification Costs

If equipment doesn't meet your URS or GMP requirements, you'll need a full re-qualification cycle — costing 3–6 months and significant budget. This is one of the most common pitfalls in new plant setups.

Regulatory Hold & Batch Failures

Wrong equipment can cause critical process parameters (CPPs) to go out of range, leading to batch rejection, OOS results, and in severe cases, regulatory action or plant shutdown by CDSCO or US FDA.

Capacity Bottlenecks

Equipment that's correctly qualified but sized wrong creates production bottlenecks. Under-sized upstream equipment and over-sized downstream equipment are a hidden drain on throughput and profitability.

Plant Layout Inefficiencies

Poor process design creates unnecessary material movement, cross-contamination risks, and ISO grade violations. Getting the layout right from the start prevents expensive retrofits later.

Documentation Gaps

CDSCO inspectors and US FDA auditors both scrutinize equipment documentation closely. Missing DQ records, expired calibration certificates, or incomplete IQ/OQ reports are among the top audit findings.

Export Market Disqualification

If your equipment setup doesn't meet WHO GMP or ICH standards, your products will be barred from regulated export markets — including the EU, USA, and other SRA-regulated countries.

Step-by-Step: How We Set Up Your Process

We follow a structured, risk-based approach rooted in ICH Q9 principles and aligned with CDSCO/Schedule M (India) and US FDA cGMP requirements

Product & Process Understanding (Technology Transfer Review)

Before selecting a single piece of equipment, we analyze your product — dosage form, API sensitivity, batch size range, critical quality attributes (CQAs), and critical process parameters (CPPs). This review forms the foundation of every downstream decision and is aligned with ICH Q8 pharmaceutical development principles.

User Requirement Specification (URS) Development

We write a detailed URS that captures your process, regulatory, safety, automation, and maintenance requirements. This document is the legal and technical contract between you and your equipment vendor — and it's required by CDSCO (Revised Schedule M), US FDA (21 CFR Part 211), and WHO GMP. A well-written URS prevents scope creep and ensures your supplier delivers exactly what you need.

Equipment Selection & Vendor Evaluation

Based on the URS, we evaluate multiple vendors using a structured scoring system. Key criteria include regulatory compliance track record, material of construction (MOC) compatibility with your product, automation level, CIP/SIP capabilities, delivery timelines, and references from comparable pharma facilities. We help you avoid common pitfalls — like selecting catalog equipment that looks cheaper but fails to pass qualification.

Process Flow & Plant Layout Design

We design your process flow diagram (PFD), piping & instrumentation diagrams (P&IDs), and plant layout with GMP zone classification in mind. This includes material flow, personnel flow, HVAC zone design, contamination prevention, and cleanroom classification (ISO 5–8 / Grade A–D). The layout is optimized to minimize material handling, prevent cross-contamination, and meet fire safety and EHS standards.

Design Qualification (DQ)

Before any equipment is manufactured or purchased, we perform DQ — formally verifying that the proposed design meets all specifications in the URS and applicable GMP requirements. DQ is the first stage of the qualification lifecycle (DQ → IQ → OQ → PQ) and is required by both CDSCO Schedule M and US FDA guidelines. Skipping DQ is one of the most common causes of re-qualification downstream.

Installation & Operational Qualification (IQ / OQ)

Once equipment is delivered and installed, we execute IQ to verify it was installed exactly per manufacturer specifications and your requirements. Then OQ tests whether the equipment operates correctly across its designed range — checking all functions, safety interlocks, alarms, and controls. Every test is documented with protocols, test records, and deviation reports.

Performance Qualification (PQ) & Process Validation

PQ demonstrates that the equipment consistently performs under real production conditions — using your actual product, process parameters, and batch sizes. This links equipment performance directly to product quality. We then develop a full process validation protocol (prospective or concurrent) per ICH Q7 and FDA Process Validation Guidance (2011), ensuring your process is reproducible and in control.

GMP Documentation, SOPs & Training

We prepare all the GMP documentation your facility needs to operate and pass inspections: SOPs, batch manufacturing records (BMRs), calibration schedules, equipment logbooks, cleaning validation records, and maintenance procedures. We also conduct operator training and handover sessions so your team is confident and inspection-ready.

India vs USA: Compliance Requirements by Region

Regulatory standards differ between India and the USA. Here’s what applies to your equipment selection and process setup — depending on your market.

Requirement AreaIndia (CDSCO / Schedule M)USA (FDA / CGMP)Global (WHO / ICH)
Governing StandardIN India Drugs & Cosmetics Act 1940, Revised Schedule M (2023–24), CDSCO GuidelinesUS USA 21 CFR Part 211 (finished dosage), 21 CFR Part 210 (CGMP), FDA Guidance Documents🌐 Both WHO TRS 986, ICH Q7, Q8, Q9, Q10, PIC/S standards
Equipment QualificationDQ, IQ, OQ, PQ required for all critical equipment. Validation Master Plan (VMP) mandatory per Revised Schedule M.DQ, IQ, OQ, PQ required per FDA Equipment Qualification Guidance. Lifecycle approach under 21 CFR. Process Validation Guidance.WHO GMP requires full DQ–IQ–OQ–PQ lifecycle. ICH Q9 mandates risk-based qualification.
CalibrationTraceable calibration to national standards (NPL, India). Periodic recalibration records required per Schedule M.Calibration against NIST-traceable standards. 21 CFR 211.68 requirement for automatic/mechanical equipment.WHO TRS 986 requires calibration records with traceability to international standards.
DocumentationElectronic records (21 CFR Part 11–equivalent) now expected in Revised Schedule M. BMR, SOPs, logbooks in local/bilingual format acceptable.21 CFR Part 11 for electronic records/signatures. Complete audit trails required. FDA expects data integrity as a core focus area since 2021.WHO Annex 6 (data integrity) guidance aligns with both India and USA requirements.
Cleanroom ClassificationGrade A, B, C, D (WHO-based). Schedule M specifies cleanroom requirements by dosage form (e.g., Grade A for injectable filling).ISO 5–8 (aligned with EU GMP Annex 1 for sterile products). FDA aseptic processing guidance (2004) applies.ISO 14644 is the international reference for both India and USA implementations.
Water SystemsPurified Water (PW) and Water for Injection (WFI) per IP/BP/USP standards. Schedule M Section 6 applies.USP <1231> for water quality. 21 CFR 211.48 for water supply requirements. FDA expects continuous TOC/conductivity monitoring.WHO TRS 970 Annex 2 covers water systems for pharma manufacturing globally.
HVAC & Air HandlingSchedule M mandates HVAC qualification, pressure differentials, and AHU validation. Air change rates by zone must be documented.FDA expects HVAC validation per ISPE HVAC Guide. 21 CFR 211.46 covers ventilation, air filtration, and temperature control.ISPE Baseline Guide Vol. 2 (Facilities) used globally as HVAC design reference.
Regulatory InspectionsCDSCO + State Drug Controllers conduct joint GMP inspections (risk-based model from Jan 2026). Mandatory for license renewal.US FDA Pre-Approval Inspections (PAIs) and cGMP inspections for 510(k), NDA, ANDA applicants. Import alert risk for non-compliance.WHO Joint Assessment Inspections for COPP. WHO GMP certification required for export to many countries from India.
India-Specific Note: With CDSCO mandating inspections of all pharma factories from January 1, 2026, Indian manufacturers must ensure their equipment qualification documentation, calibration records, and process validation packages are complete. MSMEs that missed the Revised Schedule M compliance deadline are under particularly high scrutiny.

Industry Applications

Our equipment selection and process setup services cover a wide range of manufacturing sectors — each with unique regulatory and technical requirements.

Oral Solid Dosage (OSD)

Granulators, tablet presses, capsule fillers, coating pans, blenders, and conveying systems. Process setup for high-speed tablet lines with inline IPC and content uniformity testing.

Injectables & Sterile Manufacturing

Isolators, LAF units, autoclaves, filling lines, lyophilizers, and WFI generation. Grade A/B cleanroom setup and aseptic process validation per CDSCO and US FDA aseptic processing guidance.

Active Pharmaceutical Ingredients (API)

Reactors, centrifuges, dryers, milling systems, and solvent recovery units. ICH Q7 GMP compliance, containment strategy, and process safety evaluation for HPAPI handling.

Biotech & Biologics

Bioreactors, chromatography skids, TFF systems, and fill-finish lines. Process setup for mAbs, cell therapies, vaccines, and biosimilars — aligned with ICH Q5A/Q5E and US FDA biologics guidance.

Nutraceuticals & Cosmetics

Process equipment selection and GMP setup for nutraceuticals, dietary supplements, and cosmetics — aligned with FSSAI (India) and US FDA 21 CFR Part 111 / 112 as applicable.

Medical Devices & Combination Products

Manufacturing process setup for Class I–III medical devices, combination products, and in-vitro diagnostics. Aligned with CDSCO MDR 2017 (India) and 21 CFR Part 820 QSR (USA).

Typical Project Timeline

Timelines vary by project scope, but this gives you a realistic picture of what to expect. Proper planning upfront compresses timelines significantly.

Week 1–2

Gap Assessment & Scoping

Review current state, identify compliance gaps, define project scope, regulatory pathway, and resource requirements. Deliverable: Gap Assessment Report & Project Plan.

Week 3–5

URS, Process Design & Layout

Prepare URS for all critical equipment. Design process flow and plant layout with zone classifications. Review with client and get approval.

Week 6–8

Vendor Selection & DQ

Evaluate vendors, conduct factory acceptance tests (FATs) where needed, finalize procurement, and complete Design Qualification documentation.

Month 3–5

Equipment Installation & IQ/OQ

Supervise equipment installation, execute IQ and OQ protocols, handle deviations, and prepare qualification reports.

Month 5–7

PQ, Process Validation & Documentation

Complete Performance Qualification, run process validation batches, compile all GMP documentation, SOPs, and training records.

Month 7–8

Inspection Readiness & Handover

Conduct mock CDSCO/FDA audit, close out all CAPAs, train your team, and hand over a fully inspection-ready, validated facility.

Note: Greenfield pharmaceutical plant setups typically take 12–24 months. The above timeline reflects equipment qualification for a single dosage form line in an existing facility. Complex multi-product facilities or sterile manufacturing setups will require extended timelines.

Key Documentation Deliverables

Every document we prepare is GMP-grade, audit-ready, and built for long-term compliance — not just to pass a single inspection.

User Requirement Specification

Defines all technical, regulatory, and operational requirements for equipment before procurement.

Validation Master Plan

Master document covering all qualification and validation activities — required by CDSCO and US FDA.

Design Qualification Report

Formal verification that equipment design meets URS. The first stage of the qualification lifecycle.

Installation Qualification Report

Documents that equipment was installed correctly per manufacturer specs and regulatory requirements.

Operational Qualification Report

Verifies that equipment operates within defined parameters under all expected operating conditions.

Performance Qualification Report

Confirms equipment performs consistently under actual production conditions with your product.

Standard Operating Procedures

Written procedures for operation, cleaning, maintenance, calibration, and changeover of all equipment.

Batch Manufacturing Records

Complete production records for each batch — required by CDSCO, US FDA, and WHO for traceability.

Case Study: API Plant Setup for a Mid-Size Indian Pharma Company

Case Study — India | CDSCO / Schedule M | WHO GMP Export

A mid-size pharmaceutical company in Hyderabad approached our team to set up a new API manufacturing block for a cardiovascular drug — targeting both domestic CDSCO compliance and WHO GMP certification for export to regulated markets in Africa and Southeast Asia. They had purchased equipment without a formal URS and were 4 months behind schedule, with pending GMP inspection.

The Challenge

Equipment had been procured without DQ documentation. Process flow design didn’t account for solvent containment requirements. IQ/OQ protocols were missing for 6 critical equipment items. Facility had no VMP, and the validation team was under-resourced. CDSCO inspection was scheduled in 90 days.

Our Approach

We conducted a rapid gap assessment in Week 1. Prepared retrospective DQ documentation based on FAT records and vendor manuals. Redesigned process flow for solvent containment compliance. Executed IQ/OQ for all critical equipment in parallel tracks. Prepared VMP, SOPs, and calibration records within 60 days. Conducted a mock CDSCO inspection 2 weeks before the actual audit.

Regulatory Outcome

Facility passed CDSCO GMP inspection with zero critical findings and only 2 minor observations — both resolved within 30 days. WHO GMP certification was granted 5 months later, opening export to 12 new countries.

7 Common Mistakes in Equipment Selection & Process Setup

These are the most frequent and most costly mistakes we see — across Indian MSMEs and US-based manufacturers alike.

1. Buying Equipment Without a URS

Purchasing based on price or sales pitch rather than documented requirements leads to mismatched equipment that fails qualification — or requires expensive customization.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

2. Skipping Design Qualification (DQ)

DQ is often seen as optional but it's the most valuable step — catching design problems before equipment is built or installed, when corrections are cheapest.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

3. Underestimating HVAC & Cleanroom Requirements

Many Indian MSMEs upgrade equipment but fail to upgrade their HVAC systems. The Revised Schedule M now mandates HEPA filters and cleanroom classification for most dosage forms.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

5. Treating Validation as a One-Time Event

Both CDSCO and US FDA expect ongoing process monitoring and periodic requalification. Facilities that stop after initial validation quickly fall out of compliance.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

1. Designing Rooms Before Defining Process Flow

The most common mistake: drawing rooms and corridors before mapping product, material, and personnel flow. This almost always creates cross-contamination risks or inefficient layouts that regulators flag immediately.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

7. Not Planning for Scale-Up

Equipment selected for a 50 kg batch may not scale to a 500 kg batch without significant process re-development. Scalability must be part of the URS.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

1. Designing Rooms Before Defining Process Flow

The most common mistake: drawing rooms and corridors before mapping product, material, and personnel flow. This almost always creates cross-contamination risks or inefficient layouts that regulators flag immediately.

✓ Fix: Always write the URS first, then issue RFQs to vendors.

Why Choose traccglobal for Your Equipment & Process Setup?

We’re not a generic consulting firm. We specialize in pharmaceutical, biotech, and manufacturing compliance — with hands-on experience in India and the USA.

Deep Regulatory Expertise — India & USA

Our team has hands-on experience with CDSCO/Schedule M inspections, US FDA Pre-Approval Inspections (PAIs), WHO GMP audits, and ICH guideline implementation. We know what inspectors look for — and we build your documentation to pass.

End-to-End Service — From URS to Handover

We don't just give you a report and leave. We stay with you from initial gap assessment through equipment selection, qualification, process validation, documentation, and mock audit — delivering a truly turnkey solution.

Risk-Based, Practical Approach

We apply ICH Q9 risk management principles to prioritize effort and resources. Critical systems get the most rigorous qualification. Non-critical systems get appropriate, proportionate attention. No over-engineering. No under-compliance.

Scalability & Cost Optimization Built In

We help you select equipment that can grow with your business. And we find cost efficiencies — in vendor selection, documentation reuse, and qualification strategies — without cutting corners on compliance.

Proven Track Record — 150+ Successful Projects

We've helped companies ranging from Indian MSME pharma manufacturers to US-based biotech startups set up compliant, validated manufacturing processes. Our case studies span OSD, injectables, APIs, and biologics.

Transparent Communication & On-Time Delivery

We give you clear timelines, regular progress updates, and honest assessments. When there are problems — and there usually are in complex projects — we tell you immediately and present solutions, not excuses.

Frequently Asked Questions

Answers to the most common questions we get from pharmaceutical, biotech, and manufacturing companies in India and the USA.

Equipment selection in pharmaceutical manufacturing is the systematic process of choosing the right machines, systems, and utilities for your production process. It involves analyzing your product type (oral solid, injectable, API, biotech), batch size, critical quality attributes (CQAs), critical process parameters (CPPs), regulatory requirements (CDSCO, US FDA, WHO GMP), budget, and future scalability. The goal is to match the best-fit equipment to your specific process needs — not just buy the cheapest or most popular option. Poor equipment selection is one of the leading causes of GMP compliance failures and costly re-qualifications.
Under the Revised Schedule M (CDSCO), the key documents required for equipment qualification in India are: (1) User Requirement Specification (URS), (2) Validation Master Plan (VMP), (3) Design Qualification (DQ) report, (4) Installation Qualification (IQ) protocol and report, (5) Operational Qualification (OQ) protocol and report, (6) Performance Qualification (PQ) protocol and report, (7) Calibration certificates traceable to NPL (National Physical Laboratory, India), (8) Equipment SOPs, logbooks, and maintenance records, and (9) Change Control documentation for any modifications. The Revised Schedule M also expects computerized system validation (CSV) records for any equipment with software or data logging capabilities.
IQ (Installation Qualification) verifies that equipment was installed correctly — checking physical installation, utilities, materials of construction, and manufacturer specifications. OQ (Operational Qualification) tests whether the equipment operates correctly across its full design range — checking all functions, safety interlocks, alarms, and controls under worst-case conditions. PQ (Performance Qualification) confirms that the equipment performs consistently under real production conditions with your actual product and process parameters. Think of it this way: IQ asks “is it installed right?”, OQ asks “does it work correctly?”, and PQ asks “does it consistently produce good product?”
For equipment qualification of a single production line in an existing facility, the typical timeline is 3–6 months. For a complete new pharmaceutical manufacturing block (single dosage form), expect 8–12 months. A greenfield pharmaceutical plant takes 18–30 months from design to inspection-ready. These timelines can be shortened by 20–30% with proper upfront planning, an experienced team, and parallel execution of qualification activities. Key factors that extend timelines include missing URS, vendor delays, cleanroom construction issues, and incomplete documentation packages.
The Revised Schedule M (2023–2024) is CDSCO’s updated GMP standard for pharmaceutical manufacturing in India, bringing Indian requirements much closer to WHO GMP and ICH expectations. For equipment setup, it adds explicit requirements for: Design Qualification (DQ) — now mandatory, not optional; Validation Master Plans (VMPs); computer system validation for equipment with data systems; product quality reviews (PQRs); and quality risk management (QRM) in equipment qualification. Large manufacturers (turnover > ₹250 crore) were required to comply by June 2024, and MSMEs by December 31, 2025. CDSCO began mandatory inspections of all pharmaceutical factories from January 1, 2026 — making compliance urgently necessary for all manufacturers in India.
Yes — in most cases, equipment that meets US FDA cGMP requirements will also meet CDSCO/Schedule M requirements, since Revised Schedule M is aligned with WHO GMP and ICH standards. The key differences are in documentation requirements (Indian formats may differ), calibration traceability (NPL for India vs. NIST for USA), and some utility standards (e.g., water specifications reference IP vs. USP). For export-oriented Indian facilities, we recommend designing to US FDA / WHO GMP standards from the start — this gives you domestic CDSCO compliance as well as access to regulated export markets.
Project costs vary significantly based on the scope, number of equipment items, dosage form complexity, and regulatory requirements. A typical equipment qualification project for a single production line in India ranges from ₹8–25 lakhs depending on the number of equipment items and documentation scope. A full process setup and plant qualification project can range from ₹25 lakhs to ₹2+ crore for complex sterile or biotech facilities. We provide a detailed fixed-fee proposal after an initial gap assessment — so you know the full cost upfront with no surprises. We also offer phased engagement models if budget is a constraint.
Process validation is the documented evidence that your manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. It’s required by both CDSCO (Revised Schedule M Section 5) and the US FDA (21 CFR 211.68 and the 2011 FDA Process Validation Guidance). Without process validation, you cannot demonstrate to regulators that your production process is in a state of control. Modern process validation follows a lifecycle approach — covering process design, process qualification, and continued process verification (CPV) — rather than just three validation batches as was traditionally done

Ready to Build a Compliant, Efficient Facility?

Whether you’re setting up a new plant in India or the USA, upgrading to meet the Revised Schedule M, or preparing for a US FDA inspection — we’re here to help. Talk to our experts today for a free consultation.